Gut bacteria chemicals in fatty liver disease
Part of Digestive system, Hormones & metabolism clinical trials.
This study looks at whether the natural chemicals made by your gut bacteria from the food you eat could affect liver fat and health. If you have MASLD (a fatty liver condition), researchers want to measure these gut-produced substances to better understand the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of MASLD (fatty liver) confirmed by an imaging test in the last year.
- You are between 18 and 80 years old and have a Body Mass Index between 18 and 30.
- You do not have diabetes and are not taking any blood sugar-lowering medications.
- You have very regular bowel movements (every 1 to 2 days).
- You have not used antibiotics, prebiotics, or probiotics in the last 3 months, and you do not have any active serious illness.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study classifies fatty liver disease (MAFLD) by examining liver tissue samples. It aims to better understand how metabolic risk factors like high blood sugar, high blood pressure, or excess weight relate to the liver's condition.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study looks at how a specific gene (PNPLA3) might affect non-alcoholic fatty liver disease (MASLD) in people from Guadeloupe, French Guiana, and Réunion Island. It aims to understand genetic differences that could explain why some people get the disease.
Hear when a new MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.